Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
Completed
Abbott
Phase 3
2006-09-01
The primary purpose of this study is to test the safety and the effects of using an
investigational drug regimen; once daily ABT-335 (Investigational drug) administered in
combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in
patients with abnormal lipid levels in the blood.
Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
Completed
Abbott
Phase 3
2006-03-01
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335)
+ simvastatin combination therapy with ABT-335 and simvastatin monotherapy in subjects with
multiple abnormal lipid levels in the blood.
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
Completed
Abbott
Phase 3
2006-03-01
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335)
+ atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with
multiple abnormal lipid levels in the blood.
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
Completed
Abbott
Phase 3
2006-03-01
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335)
+ rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy
in subjects with multiple abnormal lipid levels in the blood.
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
Completed
AstraZeneca
Phase 1
2008-12-01
The purpose of this study is to evaluate the safety and compare the pharmacokinetic
parameters from the fixed dose combination ABT-143 relative to that from the
co-administration of the two monotherapies.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
